Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00131014 |
Recruitment Status :
Recruiting
First Posted : August 17, 2005
Last Update Posted : July 7, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Non-Hodgkin's Lymphoma Hodgkin's Disease Leukemia, Lymphocytic, Chronic Lymphoproliferative Disorders |
- Patients who participate will be asked to complete detailed family and medical history questionnaires initially, with a follow-up questionnaire every year.
- Patients will be asked to supply a blood sample and possibly a mouthwash sample, both of which can be done by mail.
- Patients will be asked to consent to the release of their lymphoma tissue block for the purposes of the study.
- Patients will be given letters of invitation for their affected relatives to invite them to participate.
Study Type : | Observational |
Estimated Enrollment : | 1500 participants |
Observational Model: | Family-Based |
Time Perspective: | Prospective |
Official Title: | Establishing a Tumor Bank and Initial Analysis of Germline and Tumor-Related Genetic Alterations in Families With Multiple Lymphoproliferative Malignancies |
Study Start Date : | August 2004 |
Estimated Primary Completion Date : | January 2023 |
Estimated Study Completion Date : | January 2023 |

Group/Cohort |
---|
Next of Kin of deceased subj by lymphoma
Next of Kin of deceased subject by lymphoma
|
Subject unaffected by lymphoma
Subject unaffected by lymphoma
|
Subject affected by lymphoma
Subject affected by lymphoma
|
- Genetic factors that contribute to the development of lymphomas and CLL [ Time Frame: Indefinite ]Genetic factors that contribute to the development of lymphomas and CLL
Biospecimen Retention: Samples With DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Any individual diagnosed with non-Hodgkin's lymphoma or Hodgkin's disease or chronic lymphocytic leukemia (CLL), who has a 1st degree relative (parent, sibling or child) with a lymphoproliferative disorder; or families in which the individual has a lymphoproliferative disorder, and an unusual clustering of frequent or premature solid tumors is also observed.
- Family members of the individual, either affected or unaffected with lymphoma, who are contacted by the individual and agree to participate in the study.
- Deceased family members may be included in the study. Public records such as death certificates may be used to confirm the history. Consent for medical records or tissue blocks will be obtained from the deceased family member's next of kin. The hierarchy of relatives defined as next of kin is spouse, offspring, parents and siblings. Archived tissue samples may be used for genetic research.
- Age > 18 years
Exclusion Criteria:
- Subjects without a family history of lymphoma

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00131014
Contact: Conner Shaughnessy | 617-582-8437 | Conner_Shaughnessy@DFCI.HARVARD.EDU | |
Contact: Jennifer Brown, MD PhD | 617-632-4564 | Jennifer_Brown@dfci.harvard.edu |
United States, Massachusetts | |
Dana-Farber Cancer Institute | Recruiting |
Boston, Massachusetts, United States, 02115 | |
Contact: Jennifer R. Brown, MD, PhD 617-632-6692 jennifer_brown@dfci.harvard.edu | |
Principal Investigator: Jennifer R. Brown, MD, PhD |
Principal Investigator: | Jennifer R. Brown, MD, PhD | Dana-Farber Cancer Institute |
Responsible Party: | Jennifer R. Brown, MD, PhD, Assistant Professor of Medicine, Dana-Farber Cancer Institute |
ClinicalTrials.gov Identifier: | NCT00131014 |
Other Study ID Numbers: |
04-165 |
First Posted: | August 17, 2005 Key Record Dates |
Last Update Posted: | July 7, 2020 |
Last Verified: | July 2020 |
Non-Hodgkin's Lymphoma Hodgkin's disease Chronic Lymphocytic Leukemia Lymphoproliferative disorder Genetics |
Lymphoproliferative Disorders Neoplasms by Histologic Type Neoplasms Lymphoma, Non-Hodgkin Hodgkin Disease Leukemia, Lymphoid Leukemia, Lymphocytic, Chronic, B-Cell |
Lymphoma Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Leukemia Leukemia, B-Cell |